Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17863
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRivalland, Gareth-
dc.contributor.authorMitchell, Paul L R-
dc.date2016-06-06-
dc.date.accessioned2018-06-18T00:11:20Z-
dc.date.available2018-06-18T00:11:20Z-
dc.date.issued2016-07-
dc.identifier.citationLancet Oncology 2016; 17(7): 860-862-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/17863-
dc.language.isoeng-
dc.titleCombined BRAF and MEK inhibition in BRAF-mutant NSCLC.-
dc.typeJournal Article-
dc.identifier.journaltitleThe Lancet Oncology-
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Victoria, Australia-
dc.identifier.affiliationUniversity of Melbourne, Victoria, Australia-
dc.identifier.affiliationThoracic Alliance for Cancer Trials, Milton, QLD, Australia-
dc.identifier.doi10.1016/S1470-2045(16)30203-0-
dc.identifier.pubmedid27283865-
dc.type.austinJournal Article-
dc.type.austinComment-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.